A Utah team has shown that inhibiting
the kinase RON could fight cancer metastasis by stimulating an
antitumor immune response.1 The findings build a case for directed
drug discovery efforts against the target, which has long been neglected in
favor of its more famous relative, MET.
Welm told SciBX that the results
will change the way RON is viewed as a cancer target.
Cain, C. SciBX 6(21); doi:10.1038/scibx.2013.507 Published online May
1. Eyob, H. et al.
Cancer Discov.; published online April 23, 2013; doi:10.1158/2159-8290.CD-12-0480
Contact: Alana L. Welm, Huntsman Cancer Institute at The University of
Utah, Salt Lake City, Utah e-mail: firstname.lastname@example.org
2. Wagh, P.K. et al.
Adv. Cancer Res. 100, 1-33 (2008)
3. Flanagan, M. BioCentury
19(24), A6-A7; June 6, 2011
4. Welm, A.L. et al.
Proc. Natl. Acad. Sci. USA 104, 7570-7575 (2007)
5. Catenacci, D.V.T. et
al. Cancer Biol. Ther. 12, 9-46 (2011)
6. Kanteti, R. et al.
Genes Chromosomes Cancer 51, 841-851 (2012)
7. Balachandran, V.P. et
al. Nat. Med. 17, 1094-1100 (2011)
AND INSTITUTIONS MENTIONED
Aslan Pharmaceuticals Pte. Ltd., Singapore
Aveo Pharmaceuticals Inc. (NASDAQ:AVEO), Cambridge, Mass.
Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.
Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind.
Exelixis Inc. (NASDAQ:EXEL), South San Francisco, Calif.
Huntsman Cancer Institute at The University of Utah, Salt Lake City, Utah
Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J.
New York University Langone Medical Center, New York, N.Y.
Novartis AG (NYSE:NVS; SIX:NOVN), Basel, Switzerland
Pfizer Inc. (NYSE:PFE), New York, N.Y.
University of California, San Francisco, Calif.
The University of Chicago, Chicago, Ill.